Kidney International Supplements最新文献_第10页

Novel therapies for diabetic kidney disease 糖尿病肾病的新疗法

IF 5.5 2区医学

Kidney International Supplements Pub Date : 2018-01-01 DOI: 10.1016/j.kisu.2017.10.005

David Z.I. Cherney , George L. Bakris

{"title":"Novel therapies for diabetic kidney disease","authors":"David Z.I. Cherney , George L. Bakris","doi":"10.1016/j.kisu.2017.10.005","DOIUrl":"10.1016/j.kisu.2017.10.005","url":null,"abstract":"<div><p>Over the past 30 years there have been many complementary therapies developed to achieve glycemic control and have an impact on cardiovascular outcomes, as well as reduce the risk of microvascular disease. The 2 most notable new entries have been the sodium–glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide-1 (GLP-1) agonists. Both these classes of agents have demonstrated reductions in cardiovascular event rates as well as reductions in blood pressure and weight. Moreover, while both have demonstrated a benefit in slowing nephropathy progression, the SGLT2 inhibitors appear to have a significantly greater effect compared with the GLP-1 agents. There is an ongoing trial specifically powered for renal disease progression, CREDENCE (Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy). Additionally, there are 2 other classes of agents being tested to slow nephropathy progression, a selective endothelin-1 receptor antagonist, atrasantan, in the SONAR (Study of Diabetic Nephropathy With Atrasentan) trial and a nonsteroidal mineralocorticoid receptor antagonist, finerenone, in the FIDELIO (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus) trial. These and other studies are discussed.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 1","pages":"Pages 18-25"},"PeriodicalIF":5.5,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2017.10.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36890414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 26

Subscription Information 订阅信息

IF 5.5 2区医学

Kidney International Supplements Pub Date : 2018-01-01 DOI: 10.1016/S2157-1716(17)30089-8

引用次数: 0

Title Page 标题页

IF 5.5 2区医学

Kidney International Supplements Pub Date : 2018-01-01 DOI: 10.1016/S2157-1716(17)30090-4

引用次数: 0

Update on reducing the development of diabetic kidney disease and cardiovascular death in diabetes 关于减少糖尿病肾病发展和糖尿病心血管死亡的最新进展

IF 5.5 2区医学

Kidney International Supplements Pub Date : 2018-01-01 DOI: 10.1016/j.kisu.2017.10.002

George L. Bakris

引用次数: 5

Diagnosis of diabetic kidney disease: state of the art and future perspective 糖尿病肾病的诊断:现状和未来展望

IF 5.5 2区医学

Kidney International Supplements Pub Date : 2018-01-01 DOI: 10.1016/j.kisu.2017.10.003

Frederik Persson , Peter Rossing

{"title":"Diagnosis of diabetic kidney disease: state of the art and future perspective","authors":"Frederik Persson , Peter Rossing","doi":"10.1016/j.kisu.2017.10.003","DOIUrl":"10.1016/j.kisu.2017.10.003","url":null,"abstract":"<div><p>Approximately 20% to 40% of patients with type 1 or type 2 diabetes mellitus develop diabetic kidney disease. This is a clinical syndrome characterized by persistent albuminuria (> 300 mg/24 h, or > 300 mg/g creatinine), a relentless decline in glomerular filtration rate (GFR), raised arterial blood pressure, and enhanced cardiovascular morbidity and mortality. There is a characteristic histopathology. In classical diabetic nephropathy, the first clinical sign is moderately increased urine albumin excretion (microalbuminuria: 30–300 mg/24 h, or 30–300 mg/g creatinine; albuminuria grade A2). Untreated microalbuminuria will gradually worsen, reaching clinical proteinuria or severely increased albuminuria (albuminuria grade A3) over 5 to 15 years. The GFR then begins to decline, and without treatment, end-stage renal failure is likely to result in 5 to 7 years. Although albuminuria is the first sign of diabetic nephropathy, the first symptom is usually peripheral edema, which occurs at a very late stage. Regular, systematic screening for diabetic kidney disease is needed in order to identify patients at risk of or with presymptomatic diabetic kidney disease. Annual monitoring of urinary albumin-to-creatinine ratio, estimated GFR, and blood pressure is recommended. Several new biomarkers or profiles of biomarkers have been investigated to improve prognostic and diagnostic precision, but none have yet been implemented in routine clinical care. In the future such techniques may pave the way for personalized treatment.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 1","pages":"Pages 2-7"},"PeriodicalIF":5.5,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2017.10.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36890412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 230

New options for the anemia of chronic kidney disease 慢性肾脏疾病贫血的新选择

IF 5.5 2区医学

Kidney International Supplements Pub Date : 2017-12-01 DOI: 10.1016/j.kisu.2017.09.002

Daniel W. Coyne , David Goldsmith , Iain C. Macdougall

引用次数: 39

Changing the paradigms for the treatment of chronic kidney disease 改变慢性肾脏疾病的治疗模式

IF 5.5 2区医学

Kidney International Supplements Pub Date : 2017-12-01 DOI: 10.1016/j.kisu.2017.09.003

Daniel W. Coyne , Csaba P. Kovesdy

引用次数: 1

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59 肾脏疾病：改善全球结果（KDIGO）CKD-MBD更新工作组。KDIGO 2017慢性肾脏疾病-矿物质和骨骼疾病（CKD-MBD）的诊断、评估、预防和治疗临床实践指南更新。肾脏国际增刊2017；7:1-59

IF 5.5 2区医学

Kidney International Supplements Pub Date : 2017-12-01 DOI: 10.1016/j.kisu.2017.10.001

引用次数: 325

New options for the management of chronic hyperkalemia 慢性高钾血症管理的新选择

IF 5.5 2区医学

Kidney International Supplements Pub Date : 2017-12-01 DOI: 10.1016/j.kisu.2017.09.001

Linda Fried , Csaba P. Kovesdy , Biff F. Palmer

引用次数: 19

Title Page 标题页

IF 5.5 2区医学

Kidney International Supplements Pub Date : 2017-12-01 DOI: 10.1016/S2157-1716(17)30067-9

引用次数: 0